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Materials and Methods: Between June 2009 and January 
2014, 100 consecutive patients (pts) (90 men, 10 women; 
mean age 60 years, range: 36-80) with HNC, were included in 
the study. The primary tumor sites were: 18% oral cavity, 20% 
oropharynx, 12% hypopharynx, 11% nasopharynx, 37% larynx, 
2% paranasal sinuses. 5% were stage I, 7% stage II, 14% stage 
III, 61% stage IVa, 7% stage IVb and 6% stage IVc. All patients 
were staged according to the American Joint Committee of 
Cancer 7th edition. We performed a contrast-enhanced CT 
and a contrast-enhanced 18FDG PET-CT which was done in the 
specific radiotherapy patient positioning. Both exams were 
compared to analyze a change in the detection of the 
primary tumor or nodal disease by 18FDG PET-CT and 
therefore a modification in the target volume planning (PTV).  
Results: In 6 pts, distance metastases were detected so that 
the intent of the treatment changed into palliative. 
Synchronous tumors were detected in 8 pts. When we 
analyzed he primary tumor defined by the CT and compared 
to the 18FDG PET-CT, it varied in 27% of cases due to 
differences in extension: 16 % increased; 11 % decreased 
which implies a variation in the delineation of tumor-GTV (T-
GTV). Referring to the nodal detection, it globally varied in 
42% cases: 5% pts were down-staged (pts staged as N2c 
changed to N2a, N2b or N1) and 3% (Nx to N0) were in fact 
false positive. This implies a reduction in the size of the 
nodal GTV (N-GTV). On the other hand, there were 17% pts 
affected by nodal disease detected thanks to the 18FDG PET-
CT but not diagnosed by the basal CT. 3% pts were staged as 
N+ (N1, N2a or N2b) but turned out into N2c. Those findings 
required to enlarge the nodal GTV. 
Conclusions: Target volume delineation is crucial in the 
radiotherapy treatment. The detection of metastases, 
additional nodal disease or larger extension in primary tumor 
has a great impact on patient management. The modification 
of the T-GTV and N-GTV implies a variation in the prescribed 
dose that could be related with the disease outcome and the 
final quality of life. 
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Purpose/Objective: To compare the survival between altered 
fractionated (AF) and conventional fractionated (CF) 
radiotherapy during concurrent chemoradiotherapy (CCRT) 
for nasopharyngeal carcinoma (NPC). 
Materials and Methods: A total of 203 patients with 1988 
AJCC stage III and IV NPC were treated by CCRT and followed 
at least 5 years. Radiotherapy was delivered by either a CF 
(70-74 Gy/35-40 fractions/7-8 weeks) or AF (72-75 Gy/45 
fractions/6 weeks) schedule. Both arms received the same 
concurrent chemotherapy, consisting of 96-hour continuous 
infusion of cisplatin and 5-FU during the first and 5th weeks 
of radiotherapy. Survival analysis was estimated by the 
Kaplan-Meier method and compared by the log-rank test. 
Results: The patient characteristics between CF and AF 
groups showed similar distribution. The 5-year nasopharynx 
failure-free, neck failure-free, and distant metastasis failure-
free survival rates were 88% vs. 86% (P=0.7781), 95% vs. 93% 
(P=0.4176), 76% vs. 73% (P=0.4029) for CF and AF arms. The 
5-year rates of overall survival (64% vs. 62%, P=0.4812) and 
progression-free survival (67% vs. 63%, P=0.3829) also showed 
similar for both groups. 
Conclusions: Conventional and altered fractionated 
radiotherapy got similar survival outcome when CCRT 
strategy was used for NPC 
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Purpose/Objective: Decision of replanning to spare the 
parotid gland (PG) during the course of locally advanced head 
and neck cancer (LAHNC) IMRT may be guided by anatomical 
markers. The objectives of the study were to identify these 
markers and generate nomograms: 
- to estimate the PG dose at the fraction; 
- to predict the PG cumulated dose delivered during the full 
treatment. 
Materials and Methods: Eighteen patients received radical 
IMRT (70Gy) for LAHNC. Weekly CTs were used to delineate 
the anatomical structures, in particular the internal and 
external PG, and to calculate the dose distributions at the 
fraction. Mean PG cumulated doses were then estimated on 
the planning CT from the weekly CTs by using deformable 
image registration. PG overdose was calculated by the 
difference between the fraction dose or cumulated dose and 
the planned dose. Correlations between anatomical markers 
and PG overdose were searched. Prediction models 
considering the population variation were generated with 
those anatomical markers. Nomograms were then generated 
to easily estimate the PG overdose. Calibration plots have 
been generated. 
Results: A total of 61% of the PG had an overdose of 3.2 Gy 
(ranging from 0.3 to 10gy) and 39% of the PGs had an 
underdose of -2.3 Gy (ranging from -0.1 to -7.9gy). At the 
fraction, the following anatomical markers were correlated 
with PG overdose (nomogram below) (p=<0.01 and R²=0.72): 
- decrease of the thickness of the neck 
- decrease of the superficial lobe of the PG 
- increase of the deep lobe of the PG 
For the cumulated dose, the PG overdose could be predicted 
from parameters calculated from the first weekly CT 
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compared to the planning CT: the CTV70 shrinkage (in cc) and 
the PG dose difference (p<0.01 and R²=0.71). 
 
 
Conclusions: Monitoring the PG volumes and the head and 
neck thickness during the course of treatment allows to 
identify PG overdose at the fraction. The first weekly CT can 
be used to predict PG overdose and therefore to target the 
patients for a dose-guided ART strategy. Other series of 
patients are needed to confirm our nomograms.  
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Purpose/Objective: Accurate target volume delineation is 
essential in the treatment of head and neck cancers using 
intensity-modulated radiotherapy (IMRT). To adapt to the 
increasing use of a volumetric outlining approach in this 
setting, contouring using a volumetric expansion method was 
incorporated with anatomical delineation into the protocols 
for De-ESCALaTE HPV, a multi-centre phase III trial for 
patients with oropharyngeal squamous cell carcinomas. 
As part of radiotherapy trials quality assurance, we evaluate 
the conformity of clinician outlining between these two 
approaches for target volume delineation. 
Materials and Methods: The first submissions of two pre-
accrual outlining benchmark cases (case 1: unilateral neck 
treatment; case 2: bilateral neck treatment) were analysed 
and compared against the trials management group (TMG) 
consensus contours for both delineation methods. The high 
dose clinical target volume (CTV) and prophylactic dose CTV 
were quantitatively assessed using Dice Similarity Coefficient 
(DSC) described by the formula:  
  
where A and B represent regions of interest. 
Results: Anatomical and volumetric outlining was assessed 
for 13 and 11 centres respectively. There was an overlap of 5 
centres which changed to using the volumetric approach 
after the protocol amendment. 
The mean DSC for delineation of high dose CTV was 
systemically greater for volumetric (case 1: 0.82, range 0.69 
– 0.96; case 2: 0.86, range 0.76 – 0.92) than anatomical (case 
1: 0.69, range 0.59 – 0.75; case 2: 0.71, range 0.60 – 0.77) 
outlining for both benchmark cases (case 1: p=0.021; case 2: 
p<0.001). 
There was no statistical difference in the mean DSC for 
prophylactic dose CTV delineation between the 2 outlining 
methods (case 1: p=0.601, case 2: p=0.735). In case 1 the 
mean DSC was 0.59 (range 0.41 – 0.70) and 0.64 (range 0.41 – 
0.82), in case 2 the mean DSC was 0.67 (range 0.61 – 0.75) 
and 0.68 (range 0.49 – 0.81) for volumetric and anatomical 
outlining respectively. 
There was greater concordance in high dose CTV delineation 
compared to prophylactic dose CTV for both benchmark cases 
using either of the two outlining methods. 
Conclusions: The volumetric approach to head and neck 
outlining appears to improve the consistency of high dose 
CTV delineation between centres and the trial consensus 
contours, suggesting that incorporating a geometric margin 
around the GTV, edited for air/bone, is likely to be less open 
to interpretation than anatomical outlining. Both delineation 
methods give rise to similar conformity for prophylactic dose 
CTV outlining, although there is more variation compared to 
high dose CTV. Adaptation of radiotherapy guidelines within 
the course of a trial can improve the concordance of clinician 
target volume definition. In addition, feedback to centres on 
pre-accrual benchmark cases and prospective/retrospective 
case reviews has been implemented to ensure trial protocol 
adherence.  
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